Rezdiffra (Resmetirom) Patent Expiration, LOE Window & CMS Spending
Rezdiffra (Resmetirom) by Madrigal: FDA Orange Book core substance LOE 2033-09-17 (last listed 2045-02-04), 0 AB generics, $87.8M 2024 CMS Part D & Medicaid spend, and $3,950 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Madrigal |
| FDA Application & Pathway | N217785 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2033-09-17 |
| Last Listed Patent or Exclusivity Date | 2045-02-04 |
| Orange Book Patents (*PED Extensions) | 8 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $87.8M |
| 2024 Medicare Part D Spend | $69.1M |
| 2024 Medicaid Spend | $18.7M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($3,950 intro WAC) |